Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.51 |
| ▸ | HPD | P32754 | 4/20 | 0.47 |
| ▸ | TLR4 | O00206 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30449234 | 1.00 | CYP19A1 (0.51) | CYP19A1HPDTLR4TLR2NPC1 | |
| SCHEMBL29617906 | 0.85 | HPD (0.52) | CYP19A1HPDNPC1KMT2AHTR1A | |
| SCHEMBL2892659 | 0.85 | HPD (0.52) | CYP19A1HPDNPC1KMT2AHTR1A | |
| SCHEMBL3874113 | 0.85 | CYP19A1 (0.50) | CYP19A1HPDTLR4TLR2NPC1 | |
| SCHEMBL11746120 | 0.84 | CYP19A1 (0.48) | CYP19A1HPDTLR4TLR2NPC1 | |
| SCHEMBL20876320 | 0.82 | NPC1 (0.54) | CYP19A1TLR4TLR2NPC1RAB9A | |
| SCHEMBL21179113 | 0.81 | CYP19A1 (0.54) | CYP19A1TLR4TLR2NPC1RAB9A | |
| SCHEMBL13424799 | 0.81 | CYP19A1 (0.53) | CYP19A1HPDTLR4TLR2NPC1 | |
| SCHEMBL30297160 | 0.80 | TDP1 (0.53) | KMT2ASMN1; SMN2HPGDTDP1 | |
| SCHEMBL6117 | 0.80 | TDP1 (0.53) | KMT2ASMN1; SMN2HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332948-A | Nitrogen-containing tetracyclic compound, preparation method and medicinal application thereof | 翰森生物有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1720868-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077944-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | CYP19A1 3449/4885HPD 1864/4885TLR4 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.